How might medicinal regulators evolve in their expectations for ENDS?
14:45 - 15:00
Industry, Policy and Regulation
While ENDS products appear to have had a significant impact on smoking within a tobacco regulatory framework, there has been zero progress in expanding market-available choice of such products within a medicinal framework. What opportunities exist to change this?
- Considerations re Safety, Efficacy, and Quality
- MHRA and FDA comparisons
- NRT & ENDS Product Characteristics
- David M. Graham Chief Impact Officer - NJOY
« Back to previous page